Critical Appraisal of the Current Ongoing Study Designs

Slides:



Advertisements
Similar presentations
Hypertrophy Arrhythmia Oxygen Consumption Vasoconstriction Atherosclerosis Insulin Resistance Renal Sympathetic Afferent Nerves: Kidney as Origin of Central.
Advertisements

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved DOC_1A.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Renal artery denervation for treatment of patients with obstructive sleep apnea and resistant hypertension: Results from the Global SYMPLICITY Registry.
Steffen Desch Thomas Okon, Diana Heinemann, Konrad Kulle, Karoline Röhnert, Melanie Sonnabend, Martin Petzold, Ulrike Müller, Gerhard Schuler, Ingo Eitel,
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
1 Chronic Treatment of Resistant Hypertension with an Implantable Medical Device: Interim 3 Year Results of Two Studies of the Rheos ® Hypertension System.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Renal denervation for resistant hypertension: it’s time to reconsider!
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Radial Frequency Ablation for Hypertension Treatment: Help or Hype? J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship.
Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Externally Delivered Focused Ultrasound for Renal.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Renal Sympathetic Denervation View From the EU
Meeting of the Balkan Excellent Centers
Prairie Cardiovascular, Springfield, IL US
Update on therapy-resistant hypertension:
Critical Appraisal of Devices for the Management of Hypertension
Renal Nerve Ablation: Will It Become the treatment
The Power of New Biomarkers to Detect Early Ischemia
Thomas F. Lüscher, FESC, FAHA, FRCP
Updates From NOTION: The First All-Comer TAVR Trial
Catheter-Based Denervation for Resistant Hypertension
Catheter-based Renal Denervation with the Symplicity System Provides Safe and Durable Blood Pressure Reduction out to Three Years Horst Sievert1, Henry.
OneShot™ Renal Denervation System
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Blood Pressure and Age in Controlling Hypertension
John C. Somberg, MD I have no real or apparent conflicts of interest to report.
From ESH 2016 | POS 7D: Jan Rosa, MD
Renal Denervation Next Steps
Renal Denervation: the St. Jude experience
Felix Mahfoud Saarland University Hospital, Homburg, Germany
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
Laura Mauri, M.D., M.Sc. Brigham and Women’s Hospital
Sympathetic Nerve Denervation for Treatment of Hypertension
SMART Study: Sympathetic Mapping/Ablation of Renal Nerves Trial
A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.
Should SPRINT change our practice?
Renal Artery Brachytherapy for Sympathetic Renal Denervation for the Treatment of Resistant Hypertension: Preclinical safety study Ron Waksman, Issi Barbash,
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Chemical Renal Denervation Update and Future Directions
Renal Denervation for Non-Hypertensive Indications
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc.
Neuro-Hormonal vs Structural Hypertension why they require different approaches Paul A. Sobotka Chief Medical Officer Rox Medical, Inc.
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
United States Preventive Services Task Force: Recommendations for ABPM
Renal Sympathetic Denervation: The Academic View
CVRx Baroreflex Activation Therapy:
Νεφρική απονεύρωση και υποστροφή βλαβών στα όργανα στόχους: συστηματική ανασκόπηση και μέτα-ανάλυση Αθανάσιος Κορδαλής1, Δημήτριος Τσιαχρής1, Παναγιώτα Πιέτρη1,
Global SYMPLICITY Registry Locations and Inclusion Criteriaa,b.
Renal Denervation Two Late-Breaking Clinical Trials.
Renal Denervation Rises From the Ashes
Resistant Hypertension: Initial Combinations of Medications
Why double blind, controlled randomized trials?
Renal Denervation Industry Perspective
Controlling High Blood Pressure
Which NOAC and When for Stroke Prevention in AF?
Controlling Elevated Blood Pressure
Volume 91, Issue 5, Pages (May 2017)
Volume 377, Issue 9771, Pages (March 2011)
Clinician Referral Training
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Percutaneous Renal Sympathetic Denervation: 2013 and Beyond
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Critical Appraisal of the Current Ongoing Study Designs CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Thomas F. Lüscher, FESC, FAHA, FRCP Professor and Chairman of Cardiology and Director, Center for Molecular Cardiology, University and University Hospital Zurich www.tomluescher.ch

Renal Denervation: New Data and Clinical Trial Desing Update CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Disclosure: Boston Scientific Research Grant Medtronic Research Grant St. Jude Educational Grant

Critical Appraisal of the Current Ongoing Study Designs CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Surgical Sympathectomy Registries Published Trial Problems of Published Trial Ongoing Trials Conclusion

Critical Appraisal of the Current Ongoing Study Designs CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Surgical Sympathectomy Registries Published Trial Problems of Published Trial Ongoing Trials Conclusion

The Sympathetic Nervous System in the Abdomen

Critical Appraisal of the Current Ongoing Study Designs Sympathectomy in Severe Hypertension: The Pioneer CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Surgical Sympathectomy Registries Published Trial Problems of Published Trial Ongoing Trials Conclusion

Sympathetic Splanchinektomy in Resistant Hypertension: Clinical Results Smithwick R, JAMA, 1953, 16:136-44

Critical Appraisal of the Current Ongoing Study Designs Registries CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Surgical Sympathectomy Registries Published Trial Problems of Published Trial Ongoing Trials Conclusion

Managing Treatment-Resistant Hypertension: Systolic-Diastolic versus Systolic Hypertension

Critical Appraisal of the Current Ongoing Study Designs CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Critical Appraisal of the Current Ongoing Study Designs Surgical Sympathectomy Registries Published Trial Problems of Published Trial Ongoing Trials Conclusion

PROs and CONs of Symplicity HTN-3 Randomized Good size (appropriate power) Double blind Sham procedure Appropriate statistics Questionalbe stabilization of BP before RNA More than 5 antihyperten-sive drugs Few recruited patients by center Unexperienced operators Single electorde device Few ablations in many patients (<6)

Impact of Number of Ablations on Change in Office SBP: Symplicity-HTN3 Matched Cohort Analysis 166 155 134 100 63 46 27 19 10 N=163 152 131 98 61 45 26 18 9 P value for trend= 0.01 Baseline SBP 178.2 180.1 178.6 180.3 178.2 180.5 179.0 179.4 179.1 179.7 178.3 181.3 181.9 182.3 183.2 182.8 185.4 189.4 95% CI P* -1.7(-7.1, 3.7) 0.54 -3.1 (-8.6, 2.4) 0.27 -5.4 (-11.3, 0.5) 0.07 -7.1 (-13.9,-0.3) 0.04 -8.4 (-17.4, 0.7) -11.5 (-21.8,-1.2) 0.03 -14.1 (-28.8, 0.7) 0.06 -12.0 (-30.0, 5.9) 0.18 -12.4 (-44.6, 19.8) 0.43 Propensity scores using baseline characteristics as covariates were used to match sham control and denervation patients *P value change in SBP for RDN compared with sham Data presented are mean (SD) David E. Kandzari et al. Eur. Heart J. 2015

DENERHTN Trial – Renal Nerve Ablation withsingle electrode radiofrequency Symplicity catheter (Medtronic)

Renal Denervation: New Data and Clinical Trial Desing Update CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update What did we learn from Symplicity HTN-3? Double-blind sham design Proper stabilization of BP important Appropriate ablation technique Better devices Distal Ablation Consistant drug regimen Resistant Hypertension?

Renal Denervation: New Data and Clinical Trial Desing Update CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update New Devices Mulitelectrode devices with option to provide A persistant nerve block are mandatory

Which patient? Old or Young? Afroamericans of caucasians? CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Which patient? Old or Young? Afroamericans of caucasians? Systolic or systolic-diastolic hypertension? Resistant or moderate? Treated or untreated?

Which patient? Old or Young? Afroamericans of caucasians? CRT 2017, Washington, DC, USA Renal Denervation: New Data and Clinical Trial Desing Update Which patient? Old or Young? Afroamericans of caucasians? Systolic or systolic-diastolic hypertension? Resistant or moderate? Treated or untreated?

Sympathetic Renal Activity is Increaed in Young, but not Old Hypertensives

Critical Appraisal of the Current Ungoing Studies Design CRT 2017, Washington, DC, USA Critical Appraisal of the Current Ungoing Studies Design Surgical renal sympathectomy works We have to prove that catheter-based ablation works, with which device and in which patients Double-blind sham design is mandatory Untreated younger hyperternsives would be the best population to prove this Thank You!